Wet AMD/intermediate AMD/GA gene therapy (Apellis Pharmaceuticals)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameWet AMD/intermediate AMD/GA gene therapy (Apellis Pharmaceuticals)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsWet age-related macular degenerationGeographic Atrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesApellis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesApellis Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsWet age-related macular degenerationGeographic Atrophy

Other Information

ATC CodeN/A
Related LinksN/A